English
Regional settings| Spread | 0.11 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 19 |
| Open | 18.38 |
| 1-Year Change | -35.17% |
| Day's Range | 18.37 - 18.97 |
Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibodies and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company is advancing a portfolio of clinical-stage XmAb drug candidates from its protein engineering technology platforms. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design technologies and XmAb development candidates with properties. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Tidutamab, XmAb841, XmAb306, AMG 509, XmAb819, XmAb104, XmAb564 and Novartis XmAb.
BRIEF: For the fiscal year ended 31 December 2021, Xencor Inc revenues increased from $122.7M to $275.1M. Net income totaled $82.6M vs. loss of $69.3M. Revenues reflect Research collaboration segment increase from $4.5M to $93M, Royalties segment increase from $17.8M to $80.3M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.21 to $1.42.
Common Stock $0.01 Par, 12/13, 200M auth., 29,422,576 issd., Insiders own approx. 56.73%
